EndoTex Interventional Systems Inc.
This article was originally published in Start Up
Executive Summary
EndoTex has chosen to focus on two of the largest non-coronary applications among vascular disorders, AAAs and carotid artery disease.
You may also be interested in...
Interview with Fred Khosravi
In Vivo interviews device entrepreneur Fred Khosravi about his secrets for success in medical device company creation. Khosravi was part of the ACS organization that eventually became Guidant, where he was on the leading edge of the coronary stent revolution. That experience provided Khosravi with a broad background in interventional cardiology devices that was useful in starting his first company, carotid stent company EndoTex Interventional Systems (which was acquired by Boston Scientific) and several other successful companies.
AAA and Vascular Device Start-Ups
The first generation less-invasive devices for abdominal aortic aneurysm (AAA) surgery haven't yet been approved and the next generation is already here.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”